Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

  • Technology appraisal guidance
  • TA157
  • Published: 
Download guidance (PDF)

6 Recommendations for further research

6.1

Further pragmatic trials of dabigatran etexilate compared with LMWH in both total hip replacement and total knee replacement would serve to lessen the uncertainty surrounding the effectiveness and cost effectiveness of these treatments and head-to-head trials of dabigatran etexilate versus fondaparinux would strengthen the evidence base for this comparison.